Exact Sciences to participate in September investor conference
Get Alerts EXAS Hot Sheet
Join SI Premium – FREE
MADISON, Wis., Sept. 1, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
- Baird Global Healthcare Conference, New YorkFireside chat on Tuesday, September 13, 2022 at 3:45 p.m. ET
The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com.
About Exact Sciences Corp.A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.
Contact: Megan JonesExact Sciences Corp.[email protected]608-535-8815
View original content to download multimedia:https://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-september-investor-conference-301615980.html
SOURCE Exact Sciences Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- XLCS Partners advises CID Capital on its investment in Kaiser Garage Doors & Gates
- Menlo Business Brokerage Expands Team with Strategic Hire
- WallachBeth Capital Announces Tenon Medical Warrant Inducement for Gross Proceeds of Approximately $2,872,338
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Robert W Baird, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share